Invasive methods of hepatocellular carcinoma treatment

Инвазивные методы лечения гепатоцеллюлярной карциномы
Gulziya Ismailova 1, Eugene Yenin 2, Shokan Kaniev 3, Talgat Tajibaev 1, Altynshash Baichalova 4, Almat Chormanov 3, Bolatbek Baimakhanov 5
More Detail
1 Departments of Science Management, JSC “National scientific center of surgery”, Almaty, Kazakhstan
2 Department of Pathology, JSC “National scientific center of surgery”, Almaty, Kazakhstan
3 Department of Hepatology, JSC “National scientific center of surgery”, Almaty, Kazakhstan
4 Department of Clinical laboratory diagnostics, JSC “National scientific center of surgery”, Almaty, Kazakhstan
5 Department of Surgery, JSC “National scientific center of surgery”, Almaty, Kazakhstan
J CLIN MED KAZ, Volume 4, Issue 46, pp. 11-13.
Download Full Text (PDF)


Hepatocellular carcinoma is the fifth most common malignant neoplasm and is the third common cause of death from cancer. Despite significant advances in the development of surgical methods and new anticancer medicines, the overall survival rates HCC remain low due to high incidence of relapse or intrahepatic metastases after treatment. The mini-review is devoted to analysis of invasive treatment methods hepatocellular carcinoma for determining the tactics of surgical treatment.


Ismailova G, Yenin E, Kaniev S, Tajibaev T, Baichalova A, Chormanov A, et al. Invasive methods of hepatocellular carcinoma treatment. Journal of Clinical Medicine of Kazakhstan. 2017;4(46):11-3.


  • GLOBOCAN 2012. Еstimated cancer incidence, mortality and prevalence worldwide in 2012. Simple maps.
  • Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
  • Jin-Kyoung Oh, Hai-Rim Shin, Min Kyung Lim et al. Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area: a community-based cohort study. BMC Cancer. 2012;12:452.
  • Chen CJ, Yang HI, Su J et al.; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.
  • Masao Omata, Ann-Lii Cheng, Norihiro Kokudo et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317–370.
  • Michael A. Choti. Transplantation Versus Resection for Hepatocellular Carcinoma in the Mild Cirrhotic: Framing the Debate. J Gastrointest Surg. 2009;13:1021–22.
  • Sotiropoulos GC, Molmenti EP, Lang H. Liver transplantation for hepatocellular carcinoma in the MELD era: leading roles of MELD score, AFP level, and recipient age as predictors of survival.Dig Dis Sci. 2009;54:917.8.
  • Reena JS, Nathan PG, Jorge AM. et al. Donor Factors Similarly Impact Survival Outcome After Liver Transplantation in Hepatocellular Carcinoma and Non-hepatocellular Carcinoma Patients. Dig Dis Sci. 2014; 59:214–19.
  • Mario S, Gianluca SB, Luca F et al Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drugeluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. J Exp Clin Cancer Res. 2010;29:164-172.
  • Mituo S., Hideo U., Yasuaki Arai et al. Transcatheter Arterial Chemoembolization (TACE) with Lipiodol to Treat Hepatocellular Carcinoma: Survey Results from the TACE Study Group of Japan. Cardiovasc Intervent Radiol. 2008;31:756–61.
  • Jiazhi Li, Zhiyong Dong, Xinjing Zhang et al. Transcatheter arterial chemoembolization in combination with stereotactic body radiation therapy in primary liver carcinoma: a systematic review and meta-analysis. Int J Clin Exp Med. 2017;10(2):1816-27.
  • Andrea V, Paolo M, Andrea D et al Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol. 2006;16:661–9.
  • R Benevento, A Santoriello, G Perna et al Efficacy of percutaneous radiofrequency ablation (RFA) for hepatocellular carcinoma in elderly patients. BMC Geriatrics. 2011;11 Suppl 1:A45.
  • Xing M, Lahti S, Kokabi N, et al. 90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival. Clin Nucl Med. 2016;41(1):21-7.
  • Ting-Shuo H, Yu-Chiau Sh., Robin T. et al Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alphafetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. Systematic Reviews. 2013;2:37-45.
  • Lewandowski RJ, Kulik LM, Riaz A, et al. Comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920-8.